Table 2 Preclinical experiments and clinical trials in promising cancer target of CD112/CD112R

melanoma and colon cancer

CD112R deletion;

anti-CD112R blocking Ab, alone or in combination with anti-PD-L1 inhibitors

Increased the CD8⁺ T cells immune cell tumor infiltration; improve the antitumor body defense and suppress refractory tumor progression

[31]

endometrial, ovarian, kidney, head and neck, and lung cancers

single treatment and combination of anti-CD112R, anti-PD-1, and anti-TIGIT

Enhanced CD8⁺ T-cell effector in cancers

[33]

breast cancer

Combination of CD112R and TIGIT mAbs

Boosted cytokine production by NK cells and improved NK cell cytotoxicity and tumor-killing effect

[26]

primary peritoneal

carcinoma and microsatellite-stable colorectal cancer

single-agent anti-CD112R (COM701), combination with anti-PD-L1 inhibitor nivolumab

The clinical benefit rate was 69% in the COM701 cohort and 75% in the combination group; Pelvic metastases have regressed notably.

[62, 63]